ClinicaliQ Trial Snapshot
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07285655.
- What is being tested: L606 is being evaluated in a Phase 3 trial to assess its safety and efficacy in treating pulmonary hypertension secondary to interstitial lung disease (PH-ILD, WHO Group 3), addressing a patient population with limited treatment options.
- Patient eligibility overview: The trial enrolls participants with confirmed PH-ILD diagnosis; specific eligibility criteria typically include documented pulmonary hypertension on haemodynamic assessment and underlying interstitial lung disease, with defined functional and haemodynamic parameters.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this…
Eligibility Snapshot
- : * Participant is between 18 years to 80 years old. * Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging. * Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters: * Pulmonary vascular resistance (PVR) ≥ 320 dynes.sec/cm5 (i.e. 4 Woods Units (WU)), and * Mean Pulmonary Artery Pressure (mPAP) of ≥ 25 mmHg, and * - Pulmonary capillary wedge pressure (PCWP) or Left-Ventricular End Diastolic Pressure (LVEDP) of ≤ 15 mmHg. * EV1/FVC (ratio) > 0.70. * 6-minute walk distance ≥ 150 meters
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.